ClinicalTrials.gg
Not yet recruitingNCT07373067Updated Aug 26, 2026

Repeat Intracerebroventricular Injections of RB-ADSC in Subjects Previously Treated in RBI Protocol RB-ADSC-02

A Phase 1 interventional study of RB-ADSC in Alzheimer Disease, sponsored by Regeneration Biomedical, Inc.. Not yet recruiting. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Regeneration Biomedical, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
45 Years and older
Sex
All
01

Study summary

This is a Phase 1b Extension Trial to allow repeat intracerebroventricular injections of RB-ADSCs in subjects previously treated in and successfully completed RBI Protocol RB-ADSC-02. In the previous Phase 1 clinical trial, RB-ADSC-02, subjects with mild to moderate Alzheimer's disease (AD) received a single intraventricular injection of RB-ADSC. RB-ADSC will be delivered intracerebroventricularly every 2 months via the previously implanted Ommaya reservoir for up to 6 injections in total. The primary objective of safety is performed 2 months after the last dose administration at the month 12 follow-up visit. The secondary objective endpoint evaluations of efficacy are performed at the month 6 and 12 visits.

Read the detailed description

This is a Phase 1b Extension Trial to allow repeat intracerebroventricular injections of RB-ADSCs in subjects previously treated in and successfully completed RBI Protocol RB-ADSC-02. In the previous Phase 1 clinical trial, RB-ADSC-02, subjects with mild to moderate Alzheimer's disease (AD) received a single intraventricular injection of RB-ADSC.

RB-ADSC will be delivered intracerebroventricularly every 2 months via the previously implanted Ommaya reservoir for up to 6 injections in total. Participants will be followed for 2 months after the last administration. The primary objective is safety and tolerability of repeated dosing of RB-ADSC. Adverse events (AEs) and serious adverse events (SAEs) will be assessed by the incidence and severity of dose-limiting toxicity (DLT) and other AEs, incidence and severity of cytokine response syndrome, vital sign measurements, clinical laboratory tests and physical examination. Preliminary efficacy of repeated dosing will be evaluated with clinical assessments (MMSE, FAST, ADAS-Cog), volumetric MRI (NeuroQuant), CSF biomarkers (phosphor-Tau, total-Tau,AB-42), and diagnostic imaging comparison (Amyloid-PET).

02

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • AD
  • Autologous
  • Stem cells
  • Cell therapy
  • Alzheimer Disease
  • RB-ADSC
03

In context

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 9 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Regeneration Biomedical, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Successful completion of the Phase 1 single dose administration study of RB-ADSC, Protocol RB-ADSC-02.
  2. Written to participate in this Phase 1b Extension Study either provided by the participant or a legal representative
  3. The participant must have a relative/caregiver who is alert for possible side effects.
  4. The caregiver must separately meet the specified inclusion/exclusion criteria for caregivers for this Phase 1b Extension Study.

Exclusion criteria

Exclusion Criteria:

  1. Participant experienced treatment related SAE or DLT in Protocol RB-ADSC-02
  2. Participants who, in the opinion of the Investigator, are unsuitable for this Phase 1 Extension Study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    RB-ADSC low dose

    Participants will receive 2x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir every 2 months for up to a total of 6 doses

    Biological: RB-ADSC

  • Experimental
    RB-ADSC medium dose

    Participants will receive 5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir every 2 months for up to a total of 6 doses

    Biological: RB-ADSC

  • Experimental
    RB-ADSC high dose

    Participants will receive 10x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir every 2 months for up to a total of 6 doses

    Biological: RB-ADSC

Interventions

  • BiologicalRB-ADSC

    Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

06

What researchers measure

Primary outcomes

  1. The safety of repeated RB-ADSC treatment in study participants with AD

    Safety will be determined by incidence, type and severity of adverse events (AE) and serious adverse events (SAE) graded according to CTCAE v5.0 and CRS revised grading system and defined by clinical relevant findings at every visit and 2 month following last dose in physical examination, vital signs and laboratory data

    Time frame: up to 12 months

Secondary outcomes

  1. Change from Baseline in cerebrospinal fluid (CSF) biomarker pTau

    CSF Biomarkers will be measured with the ADmark® phospho-tau/total-tau/ Abeta-42 assay to determine the levels of Phosphorylated-Tau protein in the cerebrospinal fluid (CSF).

    Time frame: Baseline, Month 6, Month 12

  2. Change from Baseline in cerebrospinal fluid (CSF) biomarker Total-Tau

    CSF Biomarkers will be measured with the ADmark® phospho-tau/total-tau/ Abeta-42 assay to determine the levels of Total-Tau protein in the cerebrospinal fluid (CSF).

    Time frame: Baseline, Month 6, Month 12

  3. Change from Baseline in cerebrospinal fluid (CSF) biomarker Ab42

    CSF Biomarkers will be measured with the ADmark® phospho-tau/total-tau/ Abeta-42 assay to determine the levels of Ab42 in the cerebrospinal fluid (CSF).

    Time frame: Baseline, Month 6, Month 12

  4. Change from Baseline in cerebrospinal fluid (CSF) biomarker ratios reported as amyloid-tau index (ATI)

    CSF Biomarkers will be measured with the ADmark® phospho-tau/total-tau/ Abeta-42 assay to determine the levels of Phosphorylated-Tau protein, Total-Tau protein, and Ab42 in the cerebrospinal fluid (CSF) to calculate ratios and report the amyloid-tau index (ATI).

    Time frame: Baseline, Month 6, Month 12

  5. Change from Baseline in Amyloid Positron Emission Tomography (Amyloid-PET)

    Amyloid-PET will be used to quantitatively assess amyloid plaque deposition in the brain

    Time frame: Baseline, Month 6, Month 12

  6. Change from Baseline in MMSE

    Cognitive function will be evaluated with the Mini Mental State Examination (MMSE). The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment.

    Time frame: Baseline, Month 6, Month 12

  7. Change from Baseline in ADAS-cog13

    Cognitive function will be assessed using the AD Assessment Scale - Cognitive (ADAS-cog13). The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity.

    Time frame: Baseline, Month 6, Month 12

  8. Change from Baseline in FAST

    Functional abilities will be assessed using the Functional Assessment Staging Tool (FAST). The tool consists of seven stages, with higher scores indicating more severe impairment.

    Time frame: Baseline, Month 6, Month 12

  9. Change from Baseline in MoCA

    Mild cognitive impairment and the early onset of dementia will be assessed using the Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline, Month 6, Month 12

  10. Change from Baseline in Volumetric MRI with Contrast

    Volumetric MRI with contrast of the brain will be used to detect and monitor brain abnormalities.

    Time frame: Baseline, Month 6 and Month 12

  11. Change from Baseline in NeuroQuant MRI

    NeuroQuant MRI will be used to measure volumes of brain structures.

    Time frame: Baseline, Month 6 and Month 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 24 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 28, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07373067
Lead sponsor
Regeneration Biomedical, Inc.
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 26, 2026

Study contacts

Robert Lynn
Contact
robert@regenerationbiomedical.com
877-240-1660

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion